Medical technology supplier to enter world market
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 2 May, 2000 - 22:00
WELL-KNOWN Australian medical supplier Gradipore is poised to enter an international market valued at US$10 billion after developing a platform it believes will revolutionise the industry.
The medical technology manufacturer has signed a research agreement with major international biopharmaceutical supplier, Baxter AG, covering the potential application of the Gradiflow technology to remove certain viruses from blood products.
The research agreement involves the evaluation of the technology for the removal of so-called non-enveloped viruses.
Gradipore executive chairman John Manusu said its technology had been shown to remove both enveloped and non-enveloped viruses.
“Unlike traditional methods of viral inactivation, our work suggests that the technology actually removes known viruses rather than simply rendering the virus inactive,” Mr Manusu said.
“The process used by the Gradiflow also differs from some current inactivation methods in that it does not require harsh chemical agents.
“Our technology is readily scalable and provides unique separation performance.”
Baxter is the Austrian subsidiary of Baxter lnternational Inc. Its medical products and services include blood therapies, medication delivery and renal therapy, and are used by healthcare providers and their patients in more than 100 countries.
Mr Manusu said the company had been investigating the application of the Gradiflow technology in this area.
Viral removal has recently emerged as one of the key points of entry for the technology into the blood fractionation market.
This is due to regulators and the general public bringing pressure on plasma fractionators to reduce virus levels in their products.
The pressure is driven by the growing list of blood-borne viruses, knowledge that there are other, possibly deadly, viruses as yet undiscovered and an increased awareness that there are no immediate cures for many of these viruses.
Gradipore believe the technology would be effective against viruses such as HIV and hepatitis B and C.
The medical technology manufacturer has signed a research agreement with major international biopharmaceutical supplier, Baxter AG, covering the potential application of the Gradiflow technology to remove certain viruses from blood products.
The research agreement involves the evaluation of the technology for the removal of so-called non-enveloped viruses.
Gradipore executive chairman John Manusu said its technology had been shown to remove both enveloped and non-enveloped viruses.
“Unlike traditional methods of viral inactivation, our work suggests that the technology actually removes known viruses rather than simply rendering the virus inactive,” Mr Manusu said.
“The process used by the Gradiflow also differs from some current inactivation methods in that it does not require harsh chemical agents.
“Our technology is readily scalable and provides unique separation performance.”
Baxter is the Austrian subsidiary of Baxter lnternational Inc. Its medical products and services include blood therapies, medication delivery and renal therapy, and are used by healthcare providers and their patients in more than 100 countries.
Mr Manusu said the company had been investigating the application of the Gradiflow technology in this area.
Viral removal has recently emerged as one of the key points of entry for the technology into the blood fractionation market.
This is due to regulators and the general public bringing pressure on plasma fractionators to reduce virus levels in their products.
The pressure is driven by the growing list of blood-borne viruses, knowledge that there are other, possibly deadly, viruses as yet undiscovered and an increased awareness that there are no immediate cures for many of these viruses.
Gradipore believe the technology would be effective against viruses such as HIV and hepatitis B and C.